Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 8/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865977 | 1.00 | GPR55 (0.41) | GPR55KMT2AMEN1PYGLNPSR1 | |
| SCHEMBL6076425 | 0.80 | LMNA (0.55) | GPR55KMT2AMEN1LMNAKDM4E | |
| SCHEMBL6076429 | 0.80 | LMNA (0.55) | GPR55KMT2AMEN1LMNAKDM4E | |
| SCHEMBL8870572 | 0.78 | ALDH1A1 (0.41) | GPR55KMT2AMEN1NPSR1LMNA | |
| SCHEMBL7702094 | 0.76 | SMN1; SMN2 (0.46) | GPR55KMT2AMEN1LMNAKDM4E | |
| SCHEMBL8871630 | 0.74 | ALDH1A1 (0.65) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL9618876 | 0.73 | ALDH1A1 (0.34) | GPR55KMT2AMEN1ALDH1A1 | |
| SCHEMBL13903493 | 0.73 | KDM4E (0.66) | KMT2AMEN1LMNAKDM4EALDH1A1 | |
| SCHEMBL16741108 | 0.69 | POLB (0.47) | LMNAKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1881204 | 0.69 | PYGL (0.40) | KMT2AMEN1PYGLLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1467695-A2 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6777440-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20030176495-A1 | HIV Integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-18 | — | — | US | disclosed |
| WO-2003049690-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176495-A1 | HIV Integrase inhibitors | MAPT, RIF1, HPRT1 | GPR55 3518/4885KMT2A 646/4885MEN1 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.